Stoke Therapeutics Dirección

Dirección controles de criterios 3/4

El CEO de Stoke Therapeutics' es Ed Kaye , nombrado en Oct 2017, tiene una permanencia de 6.5 años. compensación anual total es $3.53M, compuesta por 17.7% salario y 82.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.13% de las acciones de la empresa, por valor de €757.81K. La antigüedad media del equipo directivo y de la junta directiva es de 5.1 años y 5.6 años, respectivamente.

Información clave

Ed Kaye

Chief Executive Officer (CEO)

US$3.5m

Compensación total

Porcentaje del salario del CEO	17.7%
Permanencia del CEO	6.6yrs
Participación del CEO	0.1%
Permanencia media de la dirección	5.2yrs
Promedio de permanencia en la Junta Directiva	5.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Ed Kaye en comparación con los beneficios de Stoke Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$109m
Dec 31 2023	US$4m	US$626k	-US$105m
Sep 30 2023	n/a	n/a	-US$103m
Jun 30 2023	n/a	n/a	-US$105m
Mar 31 2023	n/a	n/a	-US$99m
Dec 31 2022	US$6m	US$596k	-US$101m
Sep 30 2022	n/a	n/a	-US$100m
Jun 30 2022	n/a	n/a	-US$96m
Mar 31 2022	n/a	n/a	-US$94m
Dec 31 2021	US$9m	US$568k	-US$86m
Sep 30 2021	n/a	n/a	-US$76m
Jun 30 2021	n/a	n/a	-US$67m
Mar 31 2021	n/a	n/a	-US$58m
Dec 31 2020	US$5m	US$549k	-US$52m
Sep 30 2020	n/a	n/a	-US$48m
Jun 30 2020	n/a	n/a	-US$43m
Mar 31 2020	n/a	n/a	-US$38m
Dec 31 2019	US$668k	US$477k	-US$32m
Sep 30 2019	n/a	n/a	-US$26m
Jun 30 2019	n/a	n/a	-US$21m
Mar 31 2019	n/a	n/a	-US$16m
Dec 31 2018	US$1m	US$464k	-US$13m

Compensación vs. Mercado: La compensación total de Ed($USD3.53M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.29M).

Compensación vs. Ingresos: La compensación de Ed ha sido consistente con los resultados de la empresa en el último año.

CEO

Ed Kaye (74 yo)

6.6yrs

Permanencia

US$3,533,210

Compensación

Dr. Edward M. Kaye, also known as Ed, M.D., Ph.D. has been Special Regulatory and Scientific Advisor of Sarepta Therapeutics, Inc. since June 28, 2017. He serves as Independent Director at Avidity Bioscien...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Edward Kaye	CEO & Director	6.6yrs	US$3.53m	0.13% $ 774.0k
Adrian Krainer	Co-Founder & Independent Director	no data	US$198.33k	0.78% $ 4.5m
Stephen Tulipano	Chief Financial Officer	5.2yrs	US$1.60m	0.040% $ 231.6k
Barry Ticho	Chief Medical Officer	6.6yrs	US$1.65m	0.0048% $ 27.7k
Isabel Aznarez	Co-Founder & Group VP of Discovery Research	no data	sin datos	sin datos
Huw Nash	COO & Chief Business Officer	6.6yrs	US$869.86k	sin datos
Eric Rojas	Head of Investor Relations	no data	sin datos	sin datos
Jonathan Allan	Corporate Secretary & General Counsel	3.3yrs	sin datos	0.0050% $ 29.0k
Dawn Kalmar	Chief Communications Officer	3.3yrs	sin datos	sin datos
Joan Wood	Chief Human Resources Officer	4.6yrs	sin datos	sin datos
Shamim Ruff	Chief Regulatory Officer	5.4yrs	sin datos	sin datos
Jason Hoitt	Chief Commercial Officer	less than a year	sin datos	sin datos

5.2yrs

Permanencia media

59yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0GT es experimentado (5.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Edward Kaye	CEO & Director	6.6yrs	US$3.53m	0.13% $ 774.0k
Adrian Krainer	Co-Founder & Independent Director	9.9yrs	US$198.33k	0.78% $ 4.5m
Seth Harrison	Independent Chairman of the Board	8.8yrs	US$237.33k	3.6% $ 20.9m
Arthur Levin	Independent Director	8.7yrs	US$198.33k	0.035% $ 200.7k
Ian Smith	Independent Director	less than a year	US$394.03k	0% $ 0
Garry Menzel	Independent Director	3.8yrs	US$199.33k	0% $ 0
Julie Smith	Independent Director	3.9yrs	US$206.83k	0% $ 0
Jennifer Burstein	Independent Director	4.9yrs	US$209.33k	0% $ 0
Arthur Tzianabos	Independent Director	5.7yrs	US$211.83k	0.061% $ 354.3k

5.7yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de 0GT se considera experimentada (5.6 años de antigüedad promedio).

Stoke Therapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Stoke Therapeutics, Inc. Announces Executive Changes, Effective May 7, 2024

Stoke Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

Stoke Therapeutics, Inc. Appoints Ian Smith to Board of Directors

Insufficient new directors

High number of new directors

Recent updates

First quarter 2024 earnings released: US$0.57 loss per share (vs US$0.53 loss in 1Q 2023)

Stoke Therapeutics, Inc. Announces Executive Changes, Effective May 7, 2024

Stoke Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

Stoke Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125.000004 million.

Stoke Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125.000005 million.

Stoke Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings released: US$2.38 loss per share (vs US$2.60 loss in FY 2022)

New major risk - Share price stability

New major risk - Share price stability

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.55 loss per share (vs US$0.66 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Stoke Therapeutics, Inc. Appoints Ian Smith to Board of Directors

Stoke Therapeutics, Inc. Presents Data Related to the Ongoing Clinical Development of Stk-001 for the Treatment of Dravet Syndrome

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.69 loss per share (vs US$0.63 loss in 2Q 2022)

New major risk - Revenue and earnings growth

Stoke Therapeutics, Inc. Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (Monarch & Adolescents with Dravet Syndrome

Insufficient new directors

Stoke Therapeutics, Inc. Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting

High number of new directors

Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)

Stoke Therapeutics, Inc.(NasdaqGS:STOK) dropped from Russell 2000 Growth Index

Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and Opa1 Protein Upregulation in Retinal Tissue Following Administration of Stk-002

High number of new directors

Stoke Therapeutics Announces Positive Interim Safety, PK and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome

Stoke Therapeutics Presents New Data That Demonstrate Tango Antisense Oligonucleotides (ASOs) Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Autosomal Dominant Optic Atrophy (ADOA)

New 90-day high: €52.50

New 90-day high: €46.00

Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting

Stoke Therapeutics, Inc. Announces Resignation of Robin A. Walker, Senior Vice President, Chief Legal Officer and Chief Compliance Officer

New 90-day high: €34.20

New 90-day high: €32.20

Stoke Therapeutics, Inc. Announces Plans to Move Forward with Dosing of STK-001 in Children and Adolescents in its Ongoing Phase 1/2a Monarch Study for Dravet Syndrome

New 90-day high - €26.80

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad